Spots Global Cancer Trial Database for Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer

Official Title: Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II

Study ID: NCT02068157

Conditions

Recurrent Laryngeal Squamous Cell Carcinoma

Recurrent Laryngeal Verrucous Carcinoma

Recurrent Lip and Oral Cavity Squamous Cell Carcinoma

Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary

Recurrent Oral Cavity Verrucous Carcinoma

Recurrent Oropharyngeal Squamous Cell Carcinoma

Tongue Carcinoma

Interventions

Laboratory Biomarker Analysis

Photodynamic Therapy

Porfimer Sodium

Study Description

Brief Summary: This phase II trial studies the effects of interstitial photodynamic therapy in patients with head and neck cancer that has come back. Interstitial photodynamic therapy uses a combination of laser light and a light-sensitive drug called porfimer sodium to destroy tumors. During treatment a laser light is used to activate the drug. Interstitial photodynamic therapy may be an effective treatment for head and neck cancer.

Detailed Description: PRIMARY OBJECTIVES: I. Demonstrate that our image-guided interstitial photodynamic therapy (I-PDT) dosimetry system can be used to tailor this therapy to individual patients. OUTLINE: Patients receive porfimer sodium intravenously (IV) over 3-5 minutes on day 0. Patients then undergo image-guided I-PDT on day 2. After completion of study, patients are followed up at 1 month, 2 months, 4 months, and then every 2 months for up to 12 months.